Publications en collaboration avec des chercheurs de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (20)

2024

  1. Autoimmune inflammation triggers aberrant astrocytic calcium signaling to impair synaptic plasticity

    Brain, Behavior, and Immunity, Vol. 121, pp. 192-210

2023

  1. Aluminum alters excitability by inhibiting calcium, sodium, and potassium currents in bovine chromaffin cells

    Journal of Neurochemistry, Vol. 165, Núm. 2, pp. 162-176

  2. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

    GLIA, Vol. 71, Núm. 1, pp. 103-126

  3. Spatial organization of neuron-astrocyte interactions in the somatosensory cortex

    Cerebral cortex (New York, N.Y. : 1991), Vol. 33, Núm. 8, pp. 4498-4511

  4. The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis

    Neurobiology and Physiology of the Endocannabinoid System (Elsevier), pp. 229-240

2022

  1. Cannabinoid CB1 receptor expression in oligodendrocyte progenitors of the hippocampus revealed by the NG2-EYFP-knockin mouse

    Frontiers in Neuroanatomy, Vol. 16

  2. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice

    Cell Death and Disease, Vol. 13, Núm. 7

2021

  1. Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation

    npj Parkinson's Disease, Vol. 7, Núm. 1

  2. Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1

    Histochemistry and Cell Biology, Vol. 156, Núm. 5, pp. 479-502

  3. Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain

    British Journal of Pharmacology, Vol. 178, Núm. 20, pp. 4176-4192

  4. Δ9-Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo

    GLIA, Vol. 69, Núm. 3, pp. 532-545

2020

  1. Gene expression analysis of astrocyte and microglia endocannabinoid signaling during autoimmune demyelination

    Biomolecules, Vol. 10, Núm. 9, pp. 1-19

  2. P2X7 Receptor-Dependent Layer-Specific Changes in Neuron-Microglia Reactivity in the Prefrontal Cortex of a Phencyclidine Induced Mouse Model of Schizophrenia

    Frontiers in Molecular Neuroscience, Vol. 13

  3. P2x7 receptors control demyelination and inflammation in the cuprizone model

    Brain, Behavior, and Immunity - Health, Vol. 4

2018

  1. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination

    Biochemical Pharmacology, Vol. 157, pp. 189-201

  2. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis

    Neuropharmacology, Vol. 141, pp. 181-191

2016

  1. Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model

    Genes, Vol. 7, Núm. 9

  2. Synaptic plasticity and spatial working memory are impaired in the CD mouse model of Williams-Beuren syndrome

    Molecular Brain, Vol. 9, Núm. 1

2015

  1. Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo

    GLIA, Vol. 63, Núm. 1, pp. 163-176

2013

  1. Targeting the endocannabinoid system in the treatment of fragile X syndrome

    Nature Medicine, Vol. 19, Núm. 5, pp. 603-607